Now that the company has built a new “molecular building” on Minkauva’s site, a major milestone for the company’s work on the development of the device, it is looking to the future.
Minkai, which is part of the UK-based Molecule Group, is a manufacturer of low-power devices for medical applications, but it is also looking to develop a device that could revolutionise the treatment of cancer and other serious diseases.
The device is expected to be ready for commercialisation within two years.
It is the first new molecular building ever built by the company, and its the first of its kind in the world.
It will be the first to be built on the site since the start of construction in 2010, and is set to be the world’s first commercial device for the development and manufacturing of the chemical compound N-glycolyl-2-phenylalanine (GNPA), a key ingredient in a cancer drug called CART.
The project is expected cost around €10 million and will be financed by the European Union.
The company is looking for new partners for the project.
“The project aims to use the Minkauras existing mineral building site to develop innovative and scalable manufacturing processes to produce nano- and mesophilic nano-structures,” a spokesperson said.
“The nano-architectures are expected to improve the quality of the nanomaterials by up to 10 times compared to the traditional method.”
The company has secured a grant of €1.8 million from the EU to build and test the first nano-mimetics, but a decision is yet to be taken on whether to go ahead with commercialisation.
We are looking at what we can do in the next five years to be able to put it in the hands of the people of Ireland, he added.
However, the company is working closely with its UK and US counterparts to find a way to use Minka and its Minkae site for the next phase of development.
CART, which was developed using the nano-electronics, was first tested on a pig at the start, but now, the team is keen to build on the success and use it in patients with cancer.
“We are now looking at all of the opportunities that are in front of us to use nano-mechanical structures for clinical applications,” said Professor Dermot Kavanagh, head of Molecular Biology at the University of Dundee.
“These structures are the next frontier in medical devices and it is important that we get this technology into clinical trials, where it is most likely to benefit patients.”
“We have been looking at the potential of these nanomimetics for many years,” said Dr Mark Smith, Head of Molecular Physics at the Molecule Group.
“Now, we have a new technology to help us achieve that goal.
It is an exciting time for the Molescule Group.”
In addition to building a new compound, the NanoMolecule Building is also expected to lead to the development, manufacturing and use of a new type of nano-device.
These nano-devices are made of metal nanoparticles and have an outer layer of carbon atoms which is composed of a polymer layer.
The carbon layer acts as a coating and allows the nanoparticles to act as an insulator.
While the nano structures are generally very small and can be manufactured with very little technology, the first type of nanomemetics that are likely to be produced are the ones that are the smallest, as these will allow the nano device to be placed on the skin of a patient.
There is currently no indication of when a new nano-building could be built in the UK, but in the US it is already in development.
“Our nanomodules have been developed for use in the skin for skin grafts,” said Kavanagh.
“We believe they can also be used in the clinic, where they can help reduce pain and inflammation and enhance the quality and quantity of the skin.”